These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24035782)

  • 1. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
    Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity.
    Fitch T; Lane A; McDonnell J; Bleesing J; Jordan M; Kumar A; Khandelwal P; Khoury R; Marsh R; Chandra S
    Transplant Cell Ther; 2024 Jan; 30(1):101.e1-101.e12. PubMed ID: 37821080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
    Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
    Marsh RA; Lane A; Mehta PA; Neumeier L; Jodele S; Davies SM; Filipovich AH
    Blood; 2016 Jan; 127(4):503-12. PubMed ID: 26644451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
    Haines HL; Bleesing JJ; Davies SM; Hornung L; Jordan MB; Marsh RA; Filipovich AH
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):288-92. PubMed ID: 25464116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.
    Marsh RA; Vaughn G; Kim MO; Li D; Jodele S; Joshi S; Mehta PA; Davies SM; Jordan MB; Bleesing JJ; Filipovich AH
    Blood; 2010 Dec; 116(26):5824-31. PubMed ID: 20855862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
    Patel SA; Allewelt HA; Troy JD; Martin PL; Driscoll TA; Prasad VK; Kurtzberg J; Page KM; Parikh SH
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1722-1728. PubMed ID: 28647558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease.
    Oshrine BR; Olson TS; Bunin N
    Pediatr Blood Cancer; 2014 Oct; 61(10):1852-9. PubMed ID: 24939325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.
    Allen CE; Marsh R; Dawson P; Bollard CM; Shenoy S; Roehrs P; Hanna R; Burroughs L; Kean L; Talano JA; Schultz KR; Pai SY; Baker KS; Andolina JR; Stenger EO; Connelly J; Ramirez A; Bryant C; Eapen M; Pulsipher MA
    Blood; 2018 Sep; 132(13):1438-1451. PubMed ID: 29997222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Transplant CD34
    Chandra S; Bleesing JJ; Jordan MB; Grimley MS; Khandelwal P; Davies SM; Edwards S; Leemhuis T; Marsh RA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1527-1529. PubMed ID: 29555312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
    van Besien K; Dew A; Lin S; Joseph L; Godley LA; Larson RA; Odenike T; Rich E; Stock W; Wickrema A; Artz AS
    Leuk Lymphoma; 2009 Nov; 50(11):1809-17. PubMed ID: 19821799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Outcomes of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
    Lounder DT; Khandelwal P; Chandra S; Jordan MB; Kumar AR; Grimley MS; Davies SM; Bleesing JJ; Marsh RA
    Biol Blood Marrow Transplant; 2017 May; 23(5):857-860. PubMed ID: 28219834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation].
    Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z
    Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720
    [No Abstract]   [Full Text] [Related]  

  • 16. Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
    Hamidieh AA; Pourpak Z; Hashemi S; Yari K; Fazlollahi MR; Movahedi M; Behfar M; Moin M; Ghavamzadeh A
    Eur J Haematol; 2014 Apr; 92(4):331-6. PubMed ID: 24330187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
    Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.
    Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Bone Marrow Transplant; 2014 May; 49(5):616-21. PubMed ID: 24801098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation.
    Dimitrov M; Merkle S; Cao Q; Tryon RK; Vercellotti GM; Holtan SG; Kao RL; Srikanthan M; Terezakis SA; Tolar J; Ebens CL
    Transplant Cell Ther; 2024 Oct; 30(10):1005.e1-1005.e17. PubMed ID: 39002862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.
    Lehmberg K; Albert MH; Beier R; Beutel K; Gruhn B; Kröger N; Meisel R; Schulz A; Stachel D; Woessmann W; Janka G; Müller I
    Haematologica; 2014 Jan; 99(1):180-4. PubMed ID: 24162790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.